Viprostol

Viprostol is a synthetic prostaglandin analogue used primarily in the management of gastric ulcers and for its gastroprotective properties. It is a derivative of prostaglandin E1 (PGE1) and functions by mimicking the action of natural prostaglandins in the body.

Pharmacology

Viprostol acts by binding to prostaglandin receptors on the surface of gastric epithelial cells, leading to increased secretion of mucus and bicarbonate, which help protect the gastric lining from acid damage. Additionally, it inhibits gastric acid secretion by acting on parietal cells.

Mechanism of Action

The primary mechanism of action of Viprostol involves the activation of the EP3 receptor, a subtype of the prostaglandin E receptor. This activation results in a decrease in intracellular cyclic AMP levels, leading to reduced activity of the proton pump and decreased gastric acid secretion.

Pharmacokinetics

Viprostol is rapidly absorbed following oral administration, with peak plasma concentrations occurring within 30 minutes to 1 hour. It is metabolized in the liver and has a relatively short half-life, necessitating multiple daily doses for sustained effect.

Clinical Uses

Viprostol is primarily indicated for the prevention and treatment of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers. It is also used in certain cases to manage duodenal ulcers and gastritis.

Adverse Effects

Common adverse effects of Viprostol include diarrhea, abdominal pain, and nausea. These effects are generally mild and transient. However, caution is advised in patients with pre-existing gastrointestinal disorders.

Contraindications

Viprostol is contraindicated in pregnant women due to its potential to induce uterine contractions and cause miscarriage. It should also be used with caution in patients with inflammatory bowel disease.

Also see

• Prostaglandin E1
• Gastric ulcer
• NSAID
• Gastroprotection